[Federal Register Volume 71, Number 203 (Friday, October 20, 2006)]
[Notices]
[Pages 61980-61981]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-17519]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Circulatory System Devices Panel of the Medical Devices Advisory 
Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Circulatory System Devices Panel of the Medical 
Devices Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on December 7 and 8, 2006, 
from 8 a.m. to 5:30 p.m.
    Location: Hilton Washington DC North/Gaithersburg, Salons A, B, and 
C, 620 Perry Pkwy., Gaithersburg, MD.
    Contact Person: James Swink, Center for Devices and Radiological 
Health (CDRH) (HFZ-450), Food and Drug Administration, 9200 Corporate 
Blvd., Rockville, MD 20850, 301-443-8262, ext. 163, or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area), code 3014512625. Please call the Information Line 
for up-to-date information on this meeting.
    Agenda: The committee will discuss and make recommendations 
regarding issues related to stent thrombosis in coronary drug-eluting 
stents. Background information for the topic, including the agenda and 
questions for the committee, will be available to the public 1 business 
day before the meeting on the Internet at http://www.fda.gov/cdrh/panel 
(click on Upcoming CDRH Advisory Panel/Committee Meetings).
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person on or before 
November 15, 2006. Oral presentations from the public will be scheduled 
on both days for approximately 1 hour at the beginning of committee 
deliberations and for approximately 1 hour near the end of the 
deliberations. Time allotted for each presentation may be limited. 
Those desiring to make formal oral presentations should notify the 
contact

[[Page 61981]]

person and submit a brief statement of the general nature of the 
evidence or arguments they wish to present, the names and addresses of 
proposed participants, and an indication of the approximate time 
requested to make their presentation on or before November 15, 2006.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Ann Marie Williams, 
Conference Management Staff, at 301-827-7291, at least 7 days in 
advance of the meeting.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: October 13, 2006.
Randall W. Lutter,
Associate Commissioner for Policy and Planning.
[FR Doc. E6-17519 Filed 10-19-06; 8:45 am]
BILLING CODE 4160-01-S